[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q1_USD":2375000.0,"PreferredStockSharesAuthorized_0_Q1_shares":5000000.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockValue_0_Q1_USD":0.0,"ResearchAndDevelopmentExpense_1_Q1_USD":13750000.0,"ShareBasedCompensation_1_Q1_USD":2324000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q1_pure":0.0,"Cash_0_Q1_USD":4100000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-3254000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":5000.0,"OtherAssetsNoncurrent_0_Q1_USD":12000.0,"CashEquivalentsAtCarryingValue_0_Q1_USD":104300000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-15076000.0,"IncreaseDecreaseInIncomeTaxesReceivable_1_Q1_USD":2942000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":108352000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":2324000.0,"InterestIncomeExpenseNonoperatingNet_1_Q1_USD":358000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":2324000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-17347000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"IncomeTaxesReceivableNoncurrent_0_Q1_USD":0.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"NumberOfReportableSegments_1_Q1_segment":1.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":219000.0,"IncomeTaxesReceivable_0_Q1_USD":4706000.0,"OperatingIncomeLoss_1_Q1_USD":-18748000.0,"OperatingExpenses_1_Q1_USD":18748000.0,"CommonStockSharesAuthorized_0_Q1_shares":200000000.0,"AdditionalPaidInCapital_0_Q1_USD":600182000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":8036000.0,"Assets_0_Q1_USD":115714000.0,"AssetsCurrent_0_Q1_USD":115241000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":108352000.0,"CommonStockSharesIssued_0_Q1_shares":49731811.0,"CommonStockSharesOutstanding_0_Q1_shares":49731811.0,"CommonStockValue_0_Q1_USD":50000.0,"Depreciation_1_Q1_USD":38000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.28,"GeneralAndAdministrativeExpense_1_Q1_USD":4998000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-18385000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":-3309000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":140000.0,"Liabilities_0_Q1_USD":11084000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":115714000.0,"LiabilitiesCurrent_0_Q1_USD":10978000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":179000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":0.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-17526000.0,"NetIncomeLoss_1_Q1_USD":-15076000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":2183000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":135000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-495602000.0,"StockholdersEquity_0_Q1_USD":104630000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":53426000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":106000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":326000.0,"Ticker":"ISEE","CIK":"1410939","name":"IVERIC BIO, INC.","OfficialName":"IVERIC bio Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1851737728.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200507"}]